[Correction added on 25th July 2017, after first online publication: The funding information was previously incorrect and has been amended in this version] Aim: The aim of this trial was to investigate the mechanism of action for body weight loss with semaglutide.
| INTRODUCTION
Glucagon-like peptide (GLP)-1, an incretin hormone secreted from the L-cells in the small intestine, stimulates insulin and inhibits glucagon secretions from the pancreatic islets in a glucosedependent fashion, leading to lower blood glucose levels. 1, 2 In clinical studies, GLP-1 has been shown to enhance satiety, reduce hunger and lower energy intake. 3, 4 Additionally, research conducted in rats suggests that these effects may be due to GLP-1 acting directly on receptors in the brain, affecting perceptions of the reward value of food. 5 GLP-1 receptor agonists (RAs) have been shown to reduce body weight and blood glucose levels in people who are overweight or obese, with or without diabetes. [6] [7] [8] [9] [10] Furthermore, activation of GLP-1 receptors in the human brain helps to regulate appetite and food reward. 11 Animal studies have shown that a GLP-1RA, liraglutide, can access specific areas of the brain involved in appetite regulation. 11, 12 Combined, these studies indicate a central mechanism for liraglutide-mediated weight loss due to the direct activation of discrete sites within the hypothalamus.
Semaglutide is a human GLP-1 analogue currently in development for the treatment of T2D, with a similar structure to liraglutide.
Semaglutide has 94% structural homology with native human GLP-1 13 with three important modifications: an amino acid substitution at position 8 makes semaglutide less susceptible to degradation by dipeptidyl peptidase-4; lysine acylation of the peptide backbone with a spacer and C-18 fatty di-acid chain at position 26 provides strong, specific binding to albumin; and another amino acid substitution at position 34 prevents C-18 fatty di-acid binding at the wrong site. 13 These modifications give semaglutide an extended half-life of approximately one week, 13 making it suitable for once-weekly administration. 14, 15 Once-weekly administration may improve patient compliance and quality of life, 16, 17 compared with first-generation GLP1RAs that require once-/twice-daily dosing. 18 Semaglutide is associated with dose-dependent reductions in HbA1c and body weight in individuals with diabetes. 19 As a GLP-1RA, the trial of the effect of semaglutide on appetite control may provide additional clarity concerning the role of GLP-1 receptors in this process.
The primary aim of this trial was to investigate the role of semaglutide compared with placebo on body weight loss in subjects with obesity by evaluating the effect of semaglutide on ad libitum energy intake. In addition, further aspects of homeostatic (ad libitum energy intake after lunch, appetite ratings and energy expenditure) and hedonic (food preference and food cravings) regulation of energy balance were assessed. This trial also evaluated glucose and lipid metabolism, and gastric emptying in the same subjects; these data will be reported elsewhere.
| MATERIALS AND METHODS

| Trial design
This was a single-centre, randomised, double-blind, placebo-controlled, two-period crossover trial (NCT02079870, EudraCT number:
2013-000012-24) ( Figure S1 ). 
| Interventions
The trial consisted of two 12-week crossover treatment periods, separated by a wash-out period of 5 to 7 weeks. Eligible subjects were ran- 
| Endpoints
The primary endpoint was ad libitum energy intake during a lunch meal lunch was served in excess (Appendix S1) and meal duration was recorded. At~6:00 PM, subjects were given a self-served ad libitum evening meal. For both lunch and evening meals, subjects were instructed to eat until pleasantly satiated; food consumption was measured. At~7:00 PM, subjects received their evening snack box comprised of four food categories (four items of 100 g each: high-fat and sweet; low-fat and sweet; high-fat and non-sweet; low-fat and non-sweet; individualised by preference), which they were allowed to keep until midnight. The consumption of each food category was recorded.
Subjective ratings of appetite parameters (hunger, fullness, satiety, prospective food consumption), thirst, nausea and well-being were assessed on a 100 mm visual analogue scale (VAS) before and up to 5 hours after the standardised breakfast meal, with the end of each VAS line indicating the most extreme sensation the subject had experienced. 22 Overall appetite suppression score was calculated based on the four appetite parameters (Appendix S1). 10 Palatability (taste, visual appearance, overall pleasantness) was assessed on a 100 mm VAS after each ad libitum meal.
On Day 3, fasting RMR and RQ were assessed in the morning by indirect calorimetry using a ventilated hood system. 23 RMR and RQ were calculated from the volume of oxygen consumed and volume of carbon dioxide produced (Appendix S1). Control of eating and the degree of food cravings were measured using a validated 16-item short form Control of Eating Questionnaire (COEQ), 24, 25 which included questions related to food cravings, control of eating, hunger and fullness. Based on the previous 7 days, subjects were asked to rate 15 questions on a 100 mm VAS.
One question was open-ended.
As well as measuring preferential energy intake from the evening snack box by food categories on Day 2, food preference was assessed in the fasted state at~8:00 AM on Day 3. The Leeds Food
Preference Task (LFPT) 26, 27 measures components of food preference and reward (explicit liking and implicit wanting). Validation of this method has been described previously. [28] [29] [30] Subjects were presented with pictures of food items common in the diet from the same four categories as were included in the evening snack box ( Figure S2 ). The array was either predominantly high (>50 E%) or low (<20 E%) in fat, and sweet or non-sweet (savoury) in taste, with similar familiarity and palatability. To measure explicit liking, randomised food images were presented individually, and subjects rated the extent to which they liked each food (i.e., how pleasant would it be to taste this food now?) using a 100 mm VAS ( Figure S3A ). Implicit wanting and relative preference were assessed using a forced choice methodology. Images of each of the four food categories were paired to every other category in 96 combinations. Subjects were instructed to respond as quickly and as accurately as they could to indicate their preference at that time (i.e., which food do you most want to eat now?). For implicit wanting ( Figure S3B ), reaction times for all responses were covertly recorded and mean response times for each food category (adjusted for frequency of selection) were calculated.
A positive rating indicated an immediate response to a given food category, and a negative rating indicated the opposite. The frequency-weighted algorithm was used to account for both selection and non-selection, which positively or negatively contributed to the rating, respectively.
Body composition was measured in a fasted state using air displacement plethysmography (Bodpod ® , Concord, USA), which has been validated for both normal-weight adults 31 and obese adults. 32 Body weight was measured prior to subjects entering the Bodpod and data were automatically transferred into the system. Body composition (including percentage body fat) 33 was determined via density measurements (Appendix S1).
PK endpoints (trough values) were assessed for semaglutide in steady state after 4, 8 and 12 weeks of treatment. Additionally, PK endpoints derived from the concentration-time curves (0-168 hours)
at semaglutide 1.0 mg steady state were assessed after the last dose.
Safety assessments included adverse events (AEs), hypoglycaemic events and blood pressure.
| Statistical analysis
Based on a previous trial, 10 30 subjects were needed to provide a power of 80% to detect a treatment difference in energy intake of 500 kJ at a significance level of 5%, assuming a dropout rate of about 15%. The primary endpoint was analysed in a linear mixed model on original outcome values, including treatment and period as fixed effects and subject as a random effect. Statistical analysis of the primary endpoint was performed for the full analysis set (FAS; all randomised subjects who were exposed to ≥1 dose of trial product). Energy intake, duration of ad libitum lunch and COEQ endpoints were analysed as per the primary endpoint. The ad libitum evening snack box energy intake also included interaction between treatments, with high-/low-fat and sweet/non-sweet food categories as fixed effects.
Furthermore, treatment differences were estimated for the two food categories of high-fat combined and the two categories of low-fat combined, using a linear mixed model. Treatment period, and interactions between treatments and high-/low-fat food categories were fixed effects; subject was a random effect. A similar approach was used for sweet/non-sweet food categories. Endpoints for the LFPT 28 were analysed in a statistical model similar to that used for energy intake of the evening snack box with the same four food categories.
Body weight, body composition and palatability assessments of the ad libitum lunch, evening meal and evening snack box were summarised descriptively. For VAS profiles of appetite, thirst, nausea and wellbeing, the fasting rating and mean postprandial increase in rating were analysed as per the main analysis of the primary endpoint. For the mean postprandial increase in ratings, the fasting ratings were added as a covariate. Palatability was analysed post-hoc using a linear mixed model; treatment and treatment period were fixed effects; subject was a random effect. Treatment difference in RMR was estimated post hoc using a linear mixed model; treatment, treatment period and subject were fixed effects. Treatment difference in RQ was similarly estimated. Treatment difference in RMR was also estimated with lean body mass as a covariate. All statistical analyses were two-sided and on a 5% significance level. The primary endpoint was controlled for type 1 error. Other analyses were not controlled for multiplicity.
3 | RESULTS
| Trial population
Thirty subjects were randomised to once-weekly semaglutide or placebo, and 28 completed both treatment periods of the trial. Two female subjects took contraceptives during both treatment periods.
Two subjects withdrew during treatment period 1 while receiving semaglutide due to gastrointestinal (GI) AEs. Baseline characteristics are shown in Table S1 . P < .0001) ( Figure 1A ). In addition, ad libitum food intake and meal duration were significantly lower with semaglutide vs placebo (Table 1) . Lower ad libitum energy and food intake were also observed at subsequent evening meals and the evening snacks ( Figure 1A and Table 1 ). Total energy intake across all ad libitum meals was approxi- A B FIGURE 1 Energy intake during A, ad libitum meals and B, ad libitum snack box, by food group. Abbreviations: CI, confidence interval; ETD, estimated treatment difference. Relative difference: ETD / estimated mean for placebo × 100%.
| Appetite, thirst, nausea and well-being
At the standardised breakfast meal, the fasting overall appetite suppression score was higher with semaglutide vs placebo, indicating less appetite with semaglutide (P = .0023). Overall appetite suppression scores remained higher at all time-points with semaglutide, with the difference increasing towards the end of the 5-hour postprandial period ( Figure 2A ). In general, VAS ratings of individual appetite parameters indicated less appetite with semaglutide vs placebo ( Figure 2B and C). Ratings for thirst, nausea and well-being were similar between treatments ( Figure 2C ).
Postprandial increases from fasting VAS ratings showed greater increases in satiety with semaglutide vs placebo; however, differences in the overall incremental appetite suppression score were not significant ( Figure S4 ). Postprandial increases from fasting ratings in nausea, thirst and well-being were comparable between treatments.
| Palatability
Palatability ratings were similar between treatments for both ad libitum 
| Control of eating and food cravings
The COEQ indicated less hunger, better control of eating and meal portion size, less food cravings, particularly for savoury foods, and lower ratings for the pleasantness of food for semaglutide vs placebo (Figure 3 ).
| Food preference
LFPT indicated lower explicit liking for high-fat and non-sweet foods with semaglutide vs placebo (P = .0016). Differences between treatments in explicit liking for other food categories were not significant.
Ratings of implicit wanting were lower for high-fat and non-sweet foods (P = .0203) and higher for low-fat and sweet foods (P = .0401) with semaglutide vs placebo (Table S2 ). 
| Body weight and body composition
| PK endpoints
The PK profile for semaglutide was as expected, supporting com- 
| Safety
AEs were reported more frequently with semaglutide vs placebo.
All AEs were mild or moderate in severity; no serious AEs were reported. The most common AEs were GI events. Two AEs led to withdrawal from the trial during semaglutide treatment. No severe or blood glucose-confirmed symptomatic hypoglycaemic events were reported. Observed systolic and diastolic blood pressure were stable throughout the trial for subjects receiving either treatment;
at week 12, observed mean changes from baseline were within 2 mm Hg. Given recent findings regarding the association between energy intake and changes in weight, 34, 35 it is not possible to ascertain to what degree reductions in energy intake led to the 5.0 kg loss of body weight.
Since RMR did not increase with semaglutide, it can be inferred that the whole of the body weight loss was most likely caused by a reduction in energy intake. However, RMR represents only one dimension of energy expenditure and the impact of semaglutide on the thermogenic effect or physical activity is unknown.
It should be noted that the reduction in energy intake was observed during/after body weight loss, despite known counterregulatory effects during a period with an energy deficit. 36 In terms of body composition, a three-fold greater reduction in body fat vs lean body mass was observed with semaglutide, indicating no unintentional excess loss of lean body mass.
The effect on energy intake is consistent with previous data from non-clinical 37 and clinical studies with other GLP-1RAs, 38, 39 as well as studies with native GLP-1, 3 with the reduction in energy intake correlating with reduction in body weight. 3, 38, 39 However, the effects with sema- results also corroborated actual ad libitum energy intake from the same food categories of the evening snack box, suggesting that the lower intake of fatty, energy-dense food may be the result of semaglutide-mediated reduction in preference for such foods.
Semaglutide treatment was not associated with significant changes in nausea vs placebo, either in the fasted state or postprandially. Mean palatability ratings of all meals were above 50 mm for both treatments, meaning that meals were generally well liked.
Combined, these results suggest that the lower energy intake and body weight loss with semaglutide was a general effect on both homeostatic and hedonic systems of appetite control, rather than a response caused by nausea or food aversion.
Overall, semaglutide was well tolerated. No new safety concerns were identified, in line with other GLP-1RAs and longer-term semaglutide trials. 6, 7, 40 By having subjects act as their own control, the crossover design of this trial can be considered a major strength of our overall findings.
With regard to changes in weight and body composition, however, this trial could be conversely limited by the crossover design. During the wash-out period, body weight in subjects receiving semaglutide likely had recovered before crossing over to placebo, but may not have had sufficient time to reach pre-treatment levels; which might have contributed to the small weight gain observed with placebo.
In conclusion, data after 12 weeks of treatment indicate that semaglutide-induced weight loss is probably caused by the reduced energy intake associated with reductions in appetite, and is not the result of increased energy expenditure. Other mechanisms include improvements in the control of eating, fewer food cravings and a lower relative preference for fatty, energy-dense foods. Furthermore, semaglutide-induced weight loss was associated with proportionally greater losses of body fat than lean body mass.
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